Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AcelRx Pharmaceuticals Inc.

www.acelrx.com

Latest From AcelRx Pharmaceuticals Inc.

Pain Therapeutics Appeals Remoxy CRL In Likely Last Ditch Effort To Save Abuse-Deterrent Opioid

Meeting with US FDA in January will aim to reverse fourth rejection in 10 years; firm still criticizing agency even as it works to reconcile their positions.
Complete Response Letters Neurology

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific

Opioid Prescribing Guidelines Will Be More Template Than Commandment

Commissioner Gottlieb says US FDA does not intend to force physicians to adhere to opioid prescribing guidelines being developed by National Academies of Sciences, Engineering, and Medicine.
Drug Safety Neurology

Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel

FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.
Advisory Committees Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • SuRx Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AcelRx Pharmaceuticals Inc.
  • Senior Management
  • Vincent J Angotti, CEO
    Raffi Asadorian, CFO
    Larry G Hamel, Chief Dev. Officer
    Pamela P Palmer, MD, PhD, CMO
    Mark A Evashenk, VP, Clinical Operations
    Kim Gaumer, VP, Reg. Affairs & Quality Assurance
  • Contact Info
  • AcelRx Pharmaceuticals Inc.
    Phone: (650) 216-3500
    351 Galveston Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register